SCLX vs. OMGA, MOLN, VIGL, LIFE, BCAB, SGMO, CRDL, BLUE, DBVT, and VXRT
Should you be buying Scilex stock or one of its competitors? The main competitors of Scilex include Omega Therapeutics (OMGA), Molecular Partners (MOLN), Vigil Neuroscience (VIGL), aTyr Pharma (LIFE), BioAtla (BCAB), Sangamo Therapeutics (SGMO), Cardiol Therapeutics (CRDL), bluebird bio (BLUE), DBV Technologies (DBVT), and Vaxart (VXRT). These companies are all part of the "biological products, except diagnostic" industry.
Omega Therapeutics (NASDAQ:OMGA) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, community ranking, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.
Omega Therapeutics has higher earnings, but lower revenue than Scilex. Omega Therapeutics is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.
Omega Therapeutics received 19 more outperform votes than Scilex when rated by MarketBeat users. However, 100.00% of users gave Scilex an outperform vote while only 71.88% of users gave Omega Therapeutics an outperform vote.
In the previous week, Scilex had 2 more articles in the media than Omega Therapeutics. MarketBeat recorded 16 mentions for Scilex and 14 mentions for Omega Therapeutics. Scilex's average media sentiment score of 0.71 beat Omega Therapeutics' score of 0.50 indicating that Omega Therapeutics is being referred to more favorably in the media.
Omega Therapeutics has a beta of 1.99, meaning that its share price is 99% more volatile than the S&P 500. Comparatively, Scilex has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.
97.5% of Omega Therapeutics shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 57.0% of Omega Therapeutics shares are held by insiders. Comparatively, 8.7% of Scilex shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Scilex has a net margin of -229.47% compared to Scilex's net margin of -1,868.35%. Omega Therapeutics' return on equity of 0.00% beat Scilex's return on equity.
Omega Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 314.94%. Scilex has a consensus price target of $6.00, suggesting a potential upside of 566.67%. Given Omega Therapeutics' higher possible upside, analysts clearly believe Scilex is more favorable than Omega Therapeutics.
Summary
Omega Therapeutics beats Scilex on 9 of the 17 factors compared between the two stocks.
Get Scilex News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SCLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
